T. Mehrani and M. Petri, Chapter 2 Epidemiology of the Antiphospholipid Syndrome [Internet] In: Handbook of Systemic Autoimmune Diseases, p.13, 2009.

M. Petri, Epidemiology of the Antiphospholipid Antibody Syndrome, Journal of Autoimmunity, vol.15, issue.2, pp.145-51, 2000.
DOI : 10.1006/jaut.2000.0409

M. Manoussakis, A. Tzioufas, M. Silis, P. Pange, J. Goudevenos et al., High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population, Clin Exp Immunol, vol.69, pp.557-65, 1987.

T. Quéméneur, M. Lambert, E. Hachulla, S. Dubucquoi, C. Caron et al., Significance of persistent antiphospholipid antibodies in the elderly, J Rheumatol, vol.33, pp.1559-62, 2006.

M. Biggioggero and P. Meroni, The geoepidemiology of the antiphospholipid antibody syndrome, Autoimmunity Reviews, vol.9, issue.5, pp.299-304, 2010.
DOI : 10.1016/j.autrev.2009.11.013

R. Cervera, J. Piette, J. Font, M. Khamashta, Y. Shoenfeld et al., Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis & Rheumatism, vol.15, issue.suppl 7, pp.1019-1046, 2002.
DOI : 10.1002/art.10187

J. Gómez-puerta, H. Martín, M. Amigo, M. Aguirre, M. Camps et al., Long-Term Follow-Up in 128 Patients With Primary Antiphospholipid Syndrome, Medicine, vol.84, issue.4, pp.225-255, 2005.
DOI : 10.1097/01.md.0000172074.53583.ea

R. Cervera, R. Serrano, G. Pons-estel, L. Ceberio-hualde, Y. Shoenfeld et al., Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Annals of the Rheumatic Diseases, vol.82, issue.(Suppl 7), pp.1011-1019, 2015.
DOI : 10.1136/annrheumdis-2013-204838

O. Vaarala, Editorial, Lupus, vol.25, issue.6, pp.489-90, 1997.
DOI : 10.1177/096120339700600601

P. Ambrosino, R. Lupoli, D. Minno, A. Iervolino, S. Peluso et al., Markers of cardiovascular risk in patients with antiphospholipid syndrome: A meta-analysis of literature studies, Annals of Medicine, vol.192, issue.8, pp.693-702, 2014.
DOI : 10.1016/j.autrev.2011.01.004

O. Vaarala, M. Manttari, V. Manninen, L. Tenkanen, M. Puurunen et al., Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men, Circulation, vol.91, issue.1, pp.23-30, 1995.
DOI : 10.1161/01.CIR.91.1.23

A. Bili, A. Moss, C. Francis, W. Zareba, L. Watelet et al., Anticardiolipin Antibodies and Recurrent Coronary Events : A Prospective Study of 1150 Patients, Circulation, vol.102, issue.11, pp.1258-63, 2000.
DOI : 10.1161/01.CIR.102.11.1258

R. Cervera and G. Espinosa, Update on the Catastrophic Antiphospholipid Syndrome and the ???CAPS Registry???, Seminars in Thrombosis and Hemostasis, vol.38, issue.04, pp.333-341, 2012.
DOI : 10.1055/s-0032-1304718

R. Cervera, I. Rodríguez-pintó, S. Colafrancesco, F. Conti, G. Valesini et al., 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome, 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome, pp.699-707, 2014.
DOI : 10.1016/j.autrev.2014.03.002

R. Asherson, R. Cervera, P. De-groot, D. Erkan, M. Boffa et al., Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines, Lupus, vol.42, issue.7, pp.530-534, 2003.
DOI : 10.1191/0961203303lu394oa

S. Bucciarelli, G. Espinosa, R. Cervera, D. Erkan, J. Gómez-puerta et al., Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients, Arthritis & Rheumatism, vol.11, issue.8, pp.2568-76, 2006.
DOI : 10.1002/art.22018

D. Erkan, J. Merrill, Y. Yazici, L. Sammaritano, J. Buyon et al., High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin, Arthritis & Rheumatism, vol.160, issue.6, pp.1466-1473, 2001.
DOI : 10.1002/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C

M. Martinez-zamora, S. Peralta, M. Creus, D. Tassies, J. Reverter et al., Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case???control study, Annals of the Rheumatic Diseases, vol.71, issue.1, pp.61-67, 2012.
DOI : 10.1136/ard.2011.153817

J. Alijotas-reig, R. Ferrer-oliveras, A. Ruffatti, A. Tincani, E. Lefkou et al., The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases, Autoimmunity Reviews, vol.14, issue.5, pp.387-95, 2015.
DOI : 10.1016/j.autrev.2014.12.010

L. T. Huong, D. Wechsler, B. Vauthier-brouzes, D. Duhaut, P. Costedoat et al., The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome, Rheumatology, vol.45, issue.3, pp.332-340, 2006.
DOI : 10.1093/rheumatology/kei159

I. Herraiz, D. Escribano, P. Gómez-arriaga, J. Herníndez-garcía, M. Herraiz et al., Predictive value of sequential models of uterine artery Doppler in pregnancies at high risk for pre-eclampsia, Ultrasound in Obstetrics & Gynecology, vol.110, issue.Suppl, pp.68-74, 2012.
DOI : 10.1002/uog.10147

R. Cervera, M. Khamashta, J. Font, P. Reyes, J. Vianna et al., High Prevalence of Significant Heart Valve Lesions in Patients with the 'Primary' Antiphospholipid Syndrome, Lupus, vol.1, issue.1, pp.43-50, 1991.
DOI : 10.1177/096120339100100108

R. Brey and A. Escalante, Neurological manifestations of antiphospholipid antibody syndrome, Lupus, vol.5, issue.2_suppl, pp.67-74, 1998.
DOI : 10.1177/096120339800700216

B. Godeau, J. Piette, P. Fromont, L. Intrator, A. Schaeffer et al., Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome, British Journal of Haematology, vol.98, issue.4, pp.873-882, 1997.
DOI : 10.1046/j.1365-2141.1997.3063123.x

C. Conley, . Hartman, and C. Robert, A Hemorrhagic Disorder Caused by Circulating Anticoagulant in Patients with Disseminated Lupus Erythematosous, J Lab Clin Invest, vol.31, pp.621-623, 1952.

D. Feinstein and S. Rapaport, Acquired inhibitors of blood coagulation, Prog Hemost Thromb, vol.1, pp.75-95, 1972.

E. Bowie, J. Thompson, C. Pascuzzi, and C. Owen, Thrombosis in systemic lupus erythematosus despite circulating anticoagulants, J Lab Clin Med, vol.62, pp.416-446, 1963.

R. Asherson, M. Khamashta, J. Ordi-ros, R. Derksen, S. Machin et al., The ???Primary??? Antiphospholipid Syndrome, Medicine, vol.68, issue.6, pp.366-74, 1989.
DOI : 10.1097/00005792-198911000-00004

C. Mackworth-young, S. Loizou, and M. Walport, Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder., Annals of the Rheumatic Diseases, vol.48, issue.5, pp.362-369, 1989.
DOI : 10.1136/ard.48.5.362

E. Harris, A. Gharavi, M. Boey, B. Patel, C. Mackworth-young et al., ANTICARDIOLIPIN ANTIBODIES: DETECTION BY RADIOIMMUNOASSAY AND ASSOCIATION WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS, The Lancet, vol.322, issue.8361, pp.1211-1215, 1983.
DOI : 10.1016/S0140-6736(83)91267-9

J. Brandt, D. Triplett, B. Alving, and I. Scharrer, Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH, Thromb Haemost, vol.74, pp.1185-90, 1995.

V. Pengo, A. Tripodi, G. Reber, J. Rand, T. Ortel et al., Update of the guidelines for lupus anticoagulant detection, Journal of Thrombosis and Haemostasis, vol.27, issue.10, pp.1737-1777, 2009.
DOI : 10.1111/j.1538-7836.2009.03555.x

J. Moore and C. Mohr, BIOLOGICALLY FALSE POSITIVE SEROLOGIC TESTS FOR SYPHILIS, Journal of the American Medical Association, vol.150, issue.5, pp.467-73, 1952.
DOI : 10.1001/jama.1952.03680050033010

G. Kostant, Biologically false positive reactions to serological tests for syphilis, Bull World Health Organ, vol.14, p.235, 1956.

S. Loizou, J. Mccrea, A. Rudge, R. Reynolds, C. Boyle et al., Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results, Clin Exp Immunol, vol.62, pp.738-783, 1985.

H. Mcneil, R. Simpson, C. Chesterman, and S. Krilis, Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)., Proceedings of the National Academy of Sciences, vol.87, issue.11, pp.4120-4124, 1990.
DOI : 10.1073/pnas.87.11.4120

M. Galli, P. Comfurius, C. Maassen, H. Hemker, M. De-baets et al., Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor, The Lancet, vol.335, issue.8705, pp.1544-1551, 1990.
DOI : 10.1016/0140-6736(90)91374-J

M. Galli, Anti-??2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, vol.102, issue.8, pp.2717-2740, 2003.
DOI : 10.1182/blood-2002-11-3334

E. Harris, The Second International Anti-Cardiolipin Standardization Workshop/The Kingston Anti-Phospholipid Antibody Study (KAPS) Group, American Journal of Clinical Pathology, vol.94, issue.4, pp.476-84, 1990.
DOI : 10.1093/ajcp/94.4.476

Y. Ioannou, Z. Romay-penabad, C. Pericleous, I. Giles, E. Papalardo et al., -glycoprotein??I: proof of concept, Journal of Thrombosis and Haemostasis, vol.87, issue.5, pp.833-875, 2009.
DOI : 10.1111/j.1538-7836.2009.03316.x

URL : https://hal.archives-ouvertes.fr/hal-01273468

C. Agostinis, P. Durigutto, D. Sblattero, M. Borghi, C. Grossi et al., A non-complement-fixing antibody to ??2 glycoprotein I as a novel therapy for antiphospholipid syndrome, Blood, vol.123, issue.22, pp.3478-87, 2014.
DOI : 10.1182/blood-2013-11-537704

V. Pengo, A. Ruffatti, M. Tonello, S. Cuffaro, A. Banzato et al., Antiphospholipid syndrome: antibodies to Domain 1 of ??2-glycoprotein 1 correctly classify patients at risk, Journal of Thrombosis and Haemostasis, vol.13, issue.5, pp.782-789, 2015.
DOI : 10.1111/jth.12865

D. Wahl, F. Guillemin, E. De-maistre, C. Perret-guillaume, T. Lecompte et al., Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis, Lupus, vol.333, issue.1, pp.15-22, 1998.
DOI : 10.1191/096120398678919688

P. Mustonen, K. Lehtonen, K. Javela, and M. Puurunen, Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study, Lupus, vol.35, issue.14, pp.1468-76, 2014.
DOI : 10.1001/archinte.164.1.77

V. Pengo, A. Ruffatti, C. Legnani, S. Testa, T. Fierro et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4722, 2011.
DOI : 10.1182/blood-2011-03-340232

M. Galli, D. Luciani, G. Bertolini, and T. Barbui, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003.
DOI : 10.1182/blood-2002-02-0441

A. Danowski, M. De-azevedo, J. De-souza-papi, and M. Petri, Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus, The Journal of Rheumatology, vol.36, issue.6, pp.1195-1204, 2009.
DOI : 10.3899/jrheum.081194

Q. Reynaud, J. Lega, P. Mismetti, C. Chapelle, D. Wahl et al., Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis, Autoimmunity Reviews, vol.13, issue.6, pp.595-608, 2014.
DOI : 10.1016/j.autrev.2013.11.004

V. Pengo, A. Biasiolo, C. Pegoraro, U. Cucchini, F. Noventa et al., Antibody profiles for the diagnosis of antiphospholipid syndrome, Thromb Haemost, vol.93, pp.1147-52, 2005.

V. Pengo, A. Ruffatti, C. Legnani, P. Gresele, D. Barcellona et al., Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, Journal of Thrombosis and Haemostasis, vol.106, issue.2, pp.237-279, 2010.
DOI : 10.1111/j.1538-7836.2009.03674.x

K. Duckitt, Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies, BMJ, vol.330, issue.7491, pp.565-565, 2005.
DOI : 10.1136/bmj.38380.674340.E0

L. Opatrny, M. David, S. Kahn, I. Shrier, and E. Rey, Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis, J Rheumatol, vol.33, pp.2214-2235, 2006.

J. Nodler, S. Moolamalla, E. Ledger, B. Nuwayhid, and Z. Mulla, Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset, BMC Pregnancy and Childbirth, vol.100, issue.1, p.11, 2009.
DOI : 10.1016/S0029-7844(02)02165-8

A. Ruffatti, M. Tonello, A. Cavazzana, P. Bagatella, and V. Pengo, Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy, Thrombosis Research, vol.123, issue.3, pp.482-489, 2009.
DOI : 10.1016/j.thromres.2008.03.012

A. Ruffatti, M. Tonello, M. Visentin, A. Bontadi, A. Hoxha et al., Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study, Rheumatology, vol.50, issue.9, pp.1684-1693, 2011.
DOI : 10.1093/rheumatology/ker139

E. Harris, E. Baguley, R. Asherson, and G. Hughes, Clinical and serological features of the antiphospholipid syndrome (APS), Br J Rheumatol, vol.26, p.19, 1987.

W. Wilson, A. Gharavi, T. Koike, M. Lockshin, D. Branch et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, pp.1309-1320, 1999.
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

S. Miyakis, M. Lockshin, T. Atsumi, D. Branch, R. Brey et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Journal of Thrombosis and Haemostasis, vol.75, issue.2, pp.295-306, 2006.
DOI : 10.1080/00313020310001643615

L. Arnaud, A. Mathian, A. Ruffatti, D. Erkan, M. Tektonidou et al., Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis, Autoimmunity Reviews, vol.13, issue.3, pp.281-91, 2014.
DOI : 10.1016/j.autrev.2013.10.014

L. Arnaud, A. Mathian, H. Devilliers, A. Ruffatti, M. Tektonidou et al., Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies, Autoimmunity Reviews, vol.14, issue.3, pp.192-200, 2015.
DOI : 10.1016/j.autrev.2014.10.019

G. Ruiz-irastorza, M. Cuadrado, I. Ruiz-arruza, R. Brey, M. Crowther et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies, Lupus, vol.7, issue.2, pp.206-224, 2011.
DOI : 10.1016/S0140-6736(10)60709-X

M. Khamashta, M. Cuadrado, F. Mujic, N. Taub, B. Hunt et al., The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome, New England Journal of Medicine, vol.332, issue.15, pp.993-1000, 1995.
DOI : 10.1056/NEJM199504133321504

M. Rosove and P. Brewer, Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients, Annals of Internal Medicine, vol.117, issue.4, pp.303-311, 1992.
DOI : 10.7326/0003-4819-117-4-303

R. Derksen, P. De-groot, L. Kater, and H. Nieuwenhuis, Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment., Annals of the Rheumatic Diseases, vol.52, issue.9, pp.689-92, 1993.
DOI : 10.1136/ard.52.9.689

G. Finazzi, R. Marchioli, V. Brancaccio, P. Schinco, F. Wisloff et al., A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1, Journal of Thrombosis and Haemostasis, vol.68, issue.5, pp.848-53, 2005.
DOI : 10.1001/jama.291.5.576

M. Crowther, J. Ginsberg, J. Julian, J. Denburg, J. Hirsh et al., A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome, New England Journal of Medicine, vol.349, issue.12, pp.1133-1141, 2003.
DOI : 10.1056/NEJMoa035241

J. Girón-gonzález, G. Del-río, E. Rodríguez, C. Rodríguez-martorell, J. Serrano et al., Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals, J Rheumatol, vol.31, pp.1560-1567, 2004.

A. Mak, M. Cheung, A. Cheak, and R. Ho, Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression, Rheumatology, vol.49, issue.2, pp.281-289, 2010.
DOI : 10.1093/rheumatology/kep373

D. Cohn, M. Goddijn, S. Middeldorp, J. Korevaar, F. Dawood et al., Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy, Journal of Thrombosis and Haemostasis, vol.115, issue.10, pp.2208-2221, 2010.
DOI : 10.1111/j.1538-7836.2010.04015.x

M. Empson, M. Lassere, J. Craig, and J. Scott, Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant, Cochrane Database Syst Rev, vol.99, issue.1, p.2859, 2005.
DOI : 10.1002/14651858.CD002859.pub2

L. Noble, W. Kutteh, N. Lashey, R. Franklin, and J. Herrada, Antiphospholipid antibodies associated with recurrent pregnancy loss: Prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin, Fertility and Sterility, vol.83, issue.3, pp.684-90, 2005.
DOI : 10.1016/j.fertnstert.2004.11.002

U. Fouda, A. Sayed, A. Abdou, D. Ramadan, I. Fouda et al., Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome, International Journal of Gynecology & Obstetrics, vol.8, issue.3, pp.211-216, 2011.
DOI : 10.1016/j.ijgo.2010.09.010

N. Costedoat-chalumeau, G. Guettrot-imbert, V. Leguern, G. Leroux, L. T. Huong et al., Grossesse et syndrome des antiphospholipides, La Revue de M??decine Interne, vol.33, issue.4, pp.209-225, 2012.
DOI : 10.1016/j.revmed.2012.01.003

M. Zhu, T. Olee, D. Le, R. Roubey, B. Hahn et al., Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies, British Journal of Haematology, vol.117, issue.1, pp.102-111, 1999.
DOI : 10.1021/bi960657q

P. Lieby, A. Soley, H. Levallois, B. Hugel, J. Freyssinet et al., The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity, Blood, vol.97, issue.12, pp.3820-3828, 2001.
DOI : 10.1182/blood.V97.12.3820

G. Lakos, E. Favaloro, E. Harris, P. Meroni, A. Tincani et al., International consensus guidelines on anticardiolipin and anti-??2-glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies, Report from the 13th International Congress on Antiphospholipid Antibodies, pp.1-10, 2012.
DOI : 10.1002/art.33349

S. Pierangeli, E. Favaloro, G. Lakos, P. Meroni, A. Tincani et al., Standards and reference materials for the anticardiolipin and anti-??2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies, Clinica Chimica Acta, vol.413, issue.1-2, pp.358-60, 2012.
DOI : 10.1016/j.cca.2011.09.048

A. Ruffatti, S. Olivieri, M. Tonello, M. Bortolati, E. Bison et al., Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification, Journal of Thrombosis and Haemostasis, vol.6, issue.10, pp.1693-1699, 2008.
DOI : 10.1111/j.1538-7836.2008.03121.x

I. Jennings, S. Kitchen, D. Kitchen, T. A. Woods, and I. Walker, ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?, Journal of Thrombosis and Haemostasis, vol.134, issue.10, pp.2117-2126, 2011.
DOI : 10.1111/j.1538-7836.2011.04448.x

P. Pradella, G. Azzarini, L. Santarossa, L. Caberlotto, C. Bardin et al., Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays Available from, International Congress on Antiphospholipid Antibodies. Part Two: Poster Presentations, pp.582-633, 2002.

R. Forastiero, E. Papalardo, M. Watkins, H. Nguyen, C. Quirbach et al., Evaluation of different immunoassays for the detection of antiphospholipid antibodies: Report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies, Report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies, pp.99-105, 2014.
DOI : 10.1016/j.cca.2013.11.009

M. Ramos-casals, P. Brito-zerón, M. Soto, M. Cuadrado, and M. Khamashta, Autoimmune diseases induced by TNF-targeted therapies, Best Practice & Research Clinical Rheumatology, vol.22, issue.5, pp.847-61, 2008.
DOI : 10.1016/j.berh.2008.09.008

D. Sène, J. Piette, and P. Cacoub, Antiphospholipid antibodies, antiphospholipid syndrome and infections, Autoimmunity Reviews, vol.7, issue.4, pp.272-279, 2008.
DOI : 10.1016/j.autrev.2007.10.001

A. Tincani, M. Taraborelli, and R. Cattaneo, Antiphospholipid antibodies and malignancies, Autoimmunity Reviews, vol.9, issue.4, pp.200-202, 2010.
DOI : 10.1016/j.autrev.2009.04.001

H. Okuma, Y. Kitagawa, T. Yasuda, K. Tokuoka, and S. Takagi, Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome, International Journal of Medical Sciences, vol.7, pp.15-23, 2009.
DOI : 10.7150/ijms.7.15

S. Levine, R. Brey, B. Tilley, J. Thompson, R. Sacco et al., Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke, JAMA, vol.291, pp.576-84, 2004.

S. Cuffaro, D. Ross, T. Tonello, M. Bontadi, A. Olivieri et al., Confirmation of antiphospholipid antibody positivity: a year???s results in a cohort of 113 patients, Reumatismo, vol.62, issue.1, pp.51-60, 2010.
DOI : 10.4081/reumatismo.2010.51

V. Pengo, A. Ruffatti, D. Ross, T. Tonello, M. Cuffaro et al., Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile, Journal of Thrombosis and Haemostasis, vol.38, issue.8, pp.1527-1558, 2013.
DOI : 10.1111/jth.12264

P. Giordano, R. Tesse, G. Lassandro, D. Fracchiolla, P. Ranieri et al., Clinical and laboratory characteristics of children positive for antiphospholipid antibodies, Blood Transfus Trasfus Sangue, vol.10, pp.296-301, 2012.

J. Piette and P. Cacoub, Antiphospholipid Syndrome in the Elderly: Caution, Circulation, vol.97, issue.22, pp.2195-2201, 1998.
DOI : 10.1161/01.CIR.97.22.2195

J. Criado-garcía, R. Fernández-puebla, L. Jiménez, F. Velasco, M. Santamaría et al., Retirada de la anticoagulaci??n en el s??ndrome antifosfol??pido primario cuando se negativizan los anticuerpos anticardiolipina, Revista Cl??nica Espa??ola, vol.208, issue.3, pp.135-142, 2008.
DOI : 10.1157/13115821

C. Bazán, E. , D. López, C. , M. Lozano et al., Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative, Immunologic Research, vol.11, issue.9751, pp.358-61, 2013.
DOI : 10.1007/s12026-013-8407-x